Elevance Health raised its full-year 2026 adjusted diluted earnings per share guidance to at least $27, up from a prior outlook, following second-quarter results that exceeded internal projections. The company reported adjusted diluted EPS of $7.45 for the second quarter, driven by broad-based performance across its health benefits and Carelon segments, and now views at least $26 as the appropriate earnings baseline for modeling purposes. Management reaffirmed confidence in returning to at least 12% adjusted EPS growth in 2027 off that higher baseline. Operating revenue was $49.8 billion, an increase of 0.8% year over year, while medical membership stood at 44.9 million. The company also announced plans to exit additional Medicaid markets over the next 12 to 18 months where sustainable performance is not achievable, and it intends to deploy $0.80 per share in one-time investments funded by non-recurring gains to accelerate medical cost management, member engagement, and provider connectivity capabilities in the second half of 2026.
Elevance Health IncElevance Health raised its 2026 adjusted EPS guidance to at least $27, driven by strong Q2 results and a higher earnings baseline.